Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing.

ABSTRACT:

Background

Cholangiocarcinoma (CCA) is a primary malignancy of the biliary tract with a dismal prognosis. Recently, several actionable genetic aberrations were identified with significant enrichment in intrahepatic CCA, including FGFR2 gene fusions with a prevalence of 10-15%. Recent clinical data demonstrate that these fusions are druggable in a second-line setting in advanced/metastatic disease and the efficacy in earlier lines of therapy is being evaluated in ongoing clinical trials. This scenario warrants standardised molecular profiling of these tumours.

Methods

A detailed analysis of the original genetic data from the FIGHT-202 trial, on which the approval of Pemigatinib was based, was conducted.

Results

Comparing different detection approaches and displaying re

SUBMITTER: Neumann O 

PROVIDER: S-EPMC9553883 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature